Results 241 to 250 of about 1,781,803 (291)

Glucocorticoids and invasive fungal infections

Lancet, The, 2003
Since the 1990s, opportunistic fungal infections have emerged as a substantial cause of morbidity and mortality in profoundly immunocompromised patients. Hypercortisolaemic patients, both those with endogenous Cushing's syndrome and, much more frequently, those receiving exogenous glucocorticoid therapy, are especially at risk of such infections.
Michail Lionakis
exaly   +3 more sources

Epidemiology of invasive fungal infection

International Journal of Antimicrobial Agents, 2008
Invasive fungal infection is a growing cause of morbidity and mortality in immunosuppressed patients. Furthermore, the use of azole prophylaxis against Candida species has coincided with an increase in the incidence of invasive aspergillosis and infections by other filamentous fungi such as Mucorales. New risk factors and different timescales for onset
J J, Castón-Osorio, A, Rivero, J, Torre-Cisneros   +2 more
openaire   +2 more sources

Immunomodulation of invasive fungal infections

Infectious Disease Clinics of North America, 2003
Genetic and acquired (disease- or therapy- related) host immune factors increase the risk for IFIs. In addition to antifungal drug therapy, modulation of host defenses by the use of HGFs and IFN-gamma has been supported by extensive in vitro and in vivo preclinical data.
Emmanuel, Roilides, Caron A, Lyman, Paraskevi, Panagopoulou, Stephen, Chanock   +3 more
openaire   +2 more sources

Therapy of invasive fungal infections

The Netherlands Journal of Medicine, 1999
During the past decades, the incidence and severity of invasive fungal infections has been increasing. These events have lead to the development of new antifungal agents, and amphotericin B no longer is the standard therapy for a variety of invasive mycoses. Fluconazole has become the drug of choice for treatment of C.
Kullberg, B.J., Pauw, B.E. de
openaire   +3 more sources